Valeant Pharmaceuticals North America LLC Sustainability Profile
Valeant Pharmaceuticals North America LLC, commonly referred to as Valeant, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1960, the company has established a strong presence across North America, focusing on specialty pharmaceuticals and over-the-counter products. Valeant is renowned for its diverse portfolio, which includes dermatology, ophthalmology, and neurology products, setting it apart through innovative formulations and targeted therapies. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position and expanded its product offerings. With a commitment to addressing unmet medical needs, Valeant continues to make strides in the healthcare sector, solidifying its reputation as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does Valeant Pharmaceuticals North America LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Valeant Pharmaceuticals North America LLC's score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Valeant Pharmaceuticals North America LLC's reported carbon emissions
Valeant Pharmaceuticals North America LLC, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address climate change at this time. As a current subsidiary, Valeant Pharmaceuticals may inherit climate-related data and initiatives from its parent organisation; however, no specific details regarding such cascaded information are available. The absence of emissions data and reduction initiatives highlights a potential gap in the company's climate strategy, particularly in an industry increasingly focused on sustainability and carbon footprint reduction. In the context of the pharmaceutical sector, where many companies are setting ambitious targets to reduce emissions and enhance sustainability practices, Valeant's current position may warrant further scrutiny and development of a comprehensive climate action plan.
How Carbon Intensive is Valeant Pharmaceuticals North America LLC's Industry?
How Carbon Intensive is Valeant Pharmaceuticals North America LLC's Location?
Valeant Pharmaceuticals North America LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Valeant Pharmaceuticals North America LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.